Table 1.
Variable | Frequency, n = 301 | % |
---|---|---|
Age, median (IQR), years | 60 (45–68) | — |
Female | 118 | 39.2 |
PWID | 21 | 7.0 |
Referring service | ||
orthopaedics | 114 | 37.9 |
medicine | 46 | 15.3 |
cellulitis clinic | 30 | 10 |
neurosurgery | 21 | 0.7 |
cardiovascular surgery | 16 | 5.3 |
gastroenterology | 12 | 4 |
cardiology | 11 | 3.7 |
infectious diseases | 10 | 3.3 |
otolaryngology | 8 | 2.7 |
general surgery | 6 | 2 |
plastic surgery | 6 | 2 |
thoracic surgery | 5 | 1.7 |
urology | 5 | 1.7 |
nephrology | 3 | 1 |
other | 7 | 2.3 |
Indications for treatment | ||
infected joint (with or without hardware) | 91 | 30.2 |
skin and soft tissue infection | 44 | 14.6 |
osteomyelitis | 40 | 13.3 |
bacteraemia | 34 | 11.3 |
surgical site infection (non-joint related) | 27 | 9 |
endocarditis | 22 | 7.3 |
meningitis/epidural abscess | 16 | 5.3 |
intra-abdominal infection | 13 | 4.3 |
device-related infection (excluding bacteraemia) | 8 | 2.7 |
pneumonia with S. aureus | 2 | 0.7 |
other | 4 | 1.3 |
Isolated microorganisms | ||
MRSA | 102 | 33.9 |
coagulase-negative Staphylococcus | 90 | 29.9 |
Enterococcus spp. | 20 | 6.6 |
MSSA | 6 | 2.0 |
Cutibacterium acnes | 5 | 1.7 |
culture negative | 68 | 22.6 |
other | 10 | 3.3 |
Concurrent antimicrobial therapy | ||
none | 152 | 50.5 |
cephalosporin | 54 | 17.9 |
rifampicin | 17 | 5.6 |
piperacillin/tazobactam | 34 | 11.3 |
carbapenem | 24 | 8.0 |
fluoroquinolone | 6 | 2.0 |
trimethoprim/sulfamethoxazole | 2 | 0.7 |
aminoglycosides | 2 | 0.7 |
metronidazole | 2 | 0.7 |
tetracycline | 1 | 0.3 |
clindamycin | 1 | 0.3 |
antivirals | 2 | 0.7 |
oral vancomycin | 1 | 0.3 |
daptomycin | 1 | 0.3 |
Source of culture specimen | ||
tissue | 65 | 21.6 |
blood | 52 | 17.3 |
fluid | 22 | 7.3 |
urine | 1 | 0.3 |
wound | 67 | 22.3 |
historic positive | 20 | 6.6 |
culture negative | 73 | 24.3 |
missing | 1 | 0.3 |
Target level of vancomycin trough level | ||
10–15 mg/L | 103 | 34.2 |
15–20 mg/L | 125 | 41.5 |
10–20 mg/L | 73 | 24.2 |